DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9.248,266 B2 Chandler Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9.248,266 B2 Chandler Et Al USOO9248266B2 (12) United States Patent (10) Patent No.: US 9.248,266 B2 Chandler et al. (45) Date of Patent: Feb. 2, 2016 (54) METHOD OF PERFORMINGA (58) Field of Classification Search SPHENOPALATINE GANGLION BLOCK CPC ... A61 B 17/3421: A61B 1/06; A61B 1/00082: PROCEDURE A61B 19/5202; A61M29/02: A61M29/00; A61M 2210/0681; A61M 2210/0618: A61M (71) Applicant: BIOVISION TECHNOLOGIES, LLC, 25/1002: A61M 25/10; A61M 25/04; A61M Golden, CO (US) 25/1018: A61M 2025/105: A61M 1/0009; A61M 1/062: A61M31/002: A61M31/00; (72) Inventors: Stephen W. Chandler, Montgomery, AL A61M3/0279; A61M3/0262: A61M3/0295 (US); David W. Sanso, Morrison, CO USPC ................. 600/249; 604/94.01, 95.02, 95.03, (US) 604/95.05, 96.01, 97.01, 514; 606/191, 606/192, 196, 198, 199 (73) Assignee: Biovision Technologies, LLC, Golden, See application file for complete search history. CO (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 0 days. 2.493,326 A * 1/1950 Trinder ... ... 606,196 2,847.997 A * 8, 1958 Tibone .......................... 606, 196 Appl. No.: 14/712,722 (21) (Continued) (22) Filed: May 14, 2015 FOREIGN PATENT DOCUMENTS (65) Prior Publication Data CA 2266958 A1 10, 1999 US 2015/O258315A1 Sep. 17, 2015 EP 2522386 A2 11/2012 (Continued) Related U.S. Application Data OTHER PUBLICATIONS (63) Continuation of application No. 14/699.999, filed on Apr. 29, 2015, which is a continuation-in-part of Agro, et al., “Lightwand intubation using the Trachlight(TM): a brief application No. 14/572,353, filed on Dec. 16, 2014, review of current knowledge.” Canadian Journal of Anesthesia, which is a continuation-in-part of application No. (2000), pp. 592-599. 14/298,521, filed on Jun. 6, 2014. (Continued) (60) Provisional application No. 61/917,097, filed on Dec. Primary Examiner — Eduardo C Robert 17, 2013. Assistant Examiner — Michelle C Eckman (74) Attorney, Agent, or Firm — Faegre Baker Daniels LLP (51) Int. C. A6 IB I/06 (2006.01) (57) ABSTRACT A6M 3L/00 (2006.01) Methods and devices to quickly and accurately locate the sphenopalatine ganglion (SPG) while performing a spheno (Continued) palatine ganglion block procedure that introduces a medica (52) U.S. C. tion to the SPG. The methods and devices also prevent the CPC ............ A61M31/00 (2013.01); A61B I/00135 medication applied to the SPG from flowing down a patients (2013.01); A61B I/06 (2013.01); throat during the procedure. (Continued) 15 Claims, 33 Drawing Sheets Fictisi Siiks - Masal westbule, Nose as:-garns w Y-108 - 2004 ;Pride US 9.248,266 B2 Page 2 (51) Int. Cl. 6,733,440 B2 5/2004 Ailinger et al. A6 IB I/00 (2006.01) 2.93 E. 52; Marine et al. A6 IB 7/24 (2006.01) 8.76363 $56, Ranet al. A61M 2.5/10 (2013.01) 6,793,661 B2 9/2004 Hamilton et al. (52) U.S. Cl. 6,822.213 B2 11/2004 Stark CPC ......... A61B 1724 (2013.01); A61M 25/10182 6,853,858 B2 2/2005 Shalev (2013.11); A61M 25/1002 (2013.01); A61M 6,902,535 B2 6/2005 Eberhart et al. 7,025,923 B2 4/2006 Harhen et al. 25/1011 (2013.01); A61M 2025/1052 7,056,284 B2 6/2006 Martone et al. (2013.01); A61M 2202/048 (2013.01); A61M 7,056,287 B2 6/2006 Taylor et al. 2210/06 (2013.01) 7,081,097 B2 7/2006 Martone et al. 7,112,578 B2 9/2006 Levin 7,117,033 B2 10/2006 Shalev et al. (56) References Cited 7,120,489 B2 10/2006 Shalev et al. 7,131,969 B1 1 1/2006 Hovda et al. U.S. PATENT DOCUMENTS D534,216 S 12/2006 Makower et al. 2.936,760 A * 5, 1960 Gants ....................... 604/101.03 Zig R: 1399; SRita 3,049,125 A * 8,f 1962 Kriwkowitschh .............. 606, 196 7, 190,998J. W-1 B2 3/2007 Shalev et al. 3,664,330 A 5/1972 Deutsc 7.336,309 B2 2/2008 Stark 3,747,595 A * 7/1973 Grossan ........................ 601 160 7,361,168 B2 4/2008 Makower et al. 3,766,924. A * 10/1973 Pidgeon ........................ 606, 196 7,410,480 B2 8/2008 Muni et al. 3,800,788 A 4, 1974 White 7,419,497 B2 9/2008 Muni et al. 3,850,176 A * 1 1/1974 Gottschalk .................... 606, 196 3,903,893 A * 9/1975 Scheer .......................... 606, 196 7.462,175 B2 12/2008 Chang et al. 4,592,357. A 6, 1986 Ersek 7,500,971 B2 3/2009 Chang et al. 4,606,346 A * 8, 1986 Berget al... 606, 196 23: E: 2. ity al. 4,819,619 A * 4/1989 Augustine et al. ....... 128/200.26 7561919 B2 7/2009 Shalev et al. 4,883,465 A * 1 1/1989 Brennan ........ 604,96.01 7,636,597- W - B2 12/2009 Gross et al. 4,886,493 A * 12/1989 Yee ............................... 604,516 7,640,062 B2 12/2009 Shalev 4,887,593. A 12/1989 Wiley et al. 7,641,644 B2 1/2010 Chang et al. 5,024,658 A * 6/1991 Kozlov et al. ............ 604/101.04 7,642,563 B2 1/2010 Kang et al. 5,116,311 A * 5/1992 Lofstedt ........................ 604,516 7,645,272 B2 1/2010 Chang et al. 5,189,727 A 2f1993 Guerreri 7,648,367 B1 1/2010 Makower et al. 5, 193,525 A 3,f 1993 Silverstein et al.1 7,654,997 B2 2/2010 Makower et al. 5,213,115 A 5/1993 Zytkovicz et al. 7,678,099 B2 3/2010 Ressemann et al. 5,215,536 A 6/1993 Lampropoulos et al. 5.242.400 A 9, 1993 Blake et all 7.684,859 B2 3/2010 Shalev et al. 4- 4 e et al. 7.704,259 B2 4/2010 Kaplanet al. 5,370,640 A 12/1994 Kolff 7,717.933 B2 5/2010 Becker 5,446,070 A 8/1995 Mantelle 7,720,521 B2 5/2010 Chang et al. 5483,951 A 1/1996 Frassica et al. 7,727, 186 B2 6, 2010 Makower et al. 5,514,128. A 5/1996 Hillsman et al. 7.727,226 B2 6/2010 Chang et al. 5,531,676 A 7/1996f Edwards et al. 7,729,759 B2 6/2010 Shalev et al. 5,534,242 A 7/1996 Henry 7,740,642 B2 6/2010 Becker 5.546,964 A * 8/1996 Stangerup ..................... 128/898 7,749,515 B2 7/2010 Blumenfeld 5,599,304 A 2, 1997 Shaari 7,753,929 B2 7/2010 Becker 5,626,553 A 5, 1997 Frassica et al. 7,753,930 B2 7/2010 Becker 5,647,847 A 7, 1997 Lafontaine et al. 7,771.409 B2 8/2010 Chang et al. 5,667.476 A 9, 1997 Frassica et al. 7,785,315 B1 8/2010 Muni et al. 5,676,635 A 10/1997 Levin 7,799,337 B2 9/2010 Levin 5,685,822 A 1 1/1997 Harhen T.8O3.150 B2 9, 2010 Ch 1 5,718.6665,73587. A 2,4/1998 1998 ShanthaAlarcon 7,837.672wW - B2* 11/2010 Intocciaanget al....................... 604f 540 5,752.971 A 5/1998 Rosenbluth et al. 7,842,062 B2 11/2010 Keith et al. f hanth 7,854,744 B2 12/2010 Becker $499 A .22 Shata 7,877,147 B2 1/2011 Shalev et al. 5,827.177 A 10/1998 Oneda et al. 788: E: 33. Rita 5,827,224. A * 10/1998f Shippert ......................... 604f73 7,908,000w - B2 3/2011 Shalev 5,876,32933 AA. 3/1999E. HarhenE. 7,918,871D640,374 SB2 4/20116, 2011 TruittLiu et etal. al. 6,027.478 A * 2/2000 Katz ........................ 604.102.01 D643,115 S 8/2011 Gonzales et al. 6,106,496 A 8, 2000 Arnissolle 8,010, 189 B2 8, 2011 Shalev 6,174,280 B1 1/2001f Onedah et al. 8.012,084 B2 *ck 9/2011 Machida ....................... 600,115 6,190,330 B1, 2, 2001 Harhen 8,025,635 B2 9/2011 Eaton et al. 6,322,542 B 1 * 1 1/2001 Nilson et al. .................. 604/257 6,350,231 B1 2/2002 Ailinger et al. 8,052,693 B2 11/2011 Shahoian 6.350.465 B1* 2/2002 Jonnalagadda et al. ...... 424/434 8,080,000 B2 12/2011 Makower et al. 8,088,101 B2 1/2012 Chang et al. 6,394,093 B1* 5/2002 Lethi. ... 128.207.18 8,090,433 B2 1/2012 Makower et al. 6,413.499 B1* 7/2002 Clay ............................... 424/49 8.100.933 B2 1/2012 Beck 6,432,986 B2 8/2002 Levin J. WW ecker 6,461,294 B1 10/2002 Oneda et al. .. R: 3: E. et al. 6,491,940 B1* 12/2002 Levin ............................ 424/434 J. J. ecker 6,529,756 B1 3/2003 Phan et al. 8,118,757 B2 2/2012 Morriss 6,530,881 B1 3/2003 Ailinger et al. 8,123,722 B2 2/2012 Chang et al. 6,579,582 B1 6, 2003 Harhen et al. 8,142,422 B2 3/2012 Makower et al. 6,607,546 B1 8, 2003 Murken D658,291 S 4/2012 Jenkins et al.
Load more

Recommended publications
  • United States Patent (19) 11 Patent Number: 6,046,187 Berde Et Al
    US006046187A United States Patent (19) 11 Patent Number: 6,046,187 Berde et al. (45) Date of Patent: *Apr. 4, 2000 54) FORMULATIONS AND METHODS FOR 4,389,330 6/1983 Tice et al. .......................... 427/213.36 PROVIDING PROLONGED LOCAL 4,404,183 9/1983 Kawata et al. 424/19 ANESTHESIA 4,419,340 12/1983 Yolles ............. ... 424/19 4,434,153 2/1984 Urquhart et al. 424/22 (75) Inventors: Charles B. Berde, Brookline; Robert 4,479,911 10/1984 Fong - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 264/4.6 S. Langer, Newton, both of Mass.; 4,530,840 7/1985 Tice et al. ............................... 514/179 s s 4,542,025 9/1985 Tice et al. ................................. 424/78 Joanne Curley, San Jose, Calif.; Jenny 4,557,925 12/1985 Lindahl et al. ........................... 424/19 Castillo, Philadelphia, Pa. 4,568,535 2/1986 Loesche .................................... 424/19 4,568,536 2/1986 Kronenthal et al. 424/22 73 Assignee: Children's Medical Center 4,569,837 2/1986 Suzuki et al. ............................. 424/28 Corporation, Boston, Mass. 4,585,651 4/1986 Beck et al. ................................ 424/88 4,597,960 7/1986 Cohen ...... ... 424/28 * Notice: This patent issued on a continued pros- 4,622,219 11/1986 Haynes ...................................... 424/38 ecution application filed under 37 CFR 4,622,244 11/1986 Lapka et al. ....................... 427/213.32 1.53(d), and is subject to the twenty year 4,623.588 11/1986 Nuwayser et al. ................. 428/402.24 patent154(a)(2). term provisions of 35 U.S.C. ( List continued on next page.)page. FOREIGN PATENT DOCUMENTS 21 Appl.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,617,114 B1 Fowlkes Et Al
    USOO6617114B1 (12) United States Patent (10) Patent No.: US 6,617,114 B1 Fowlkes et al. (45) Date of Patent: Sep. 9, 2003 (54) IDENTIFICATION OF DRUG OTHER PUBLICATIONS COMPLEMENTARYLIBRARIES COMBINATORIAL Bottger, et al., Identification- Y - of novel mam2 binding peptides by phage display, Oncogene, vol. 13, pp. 2141-2147, 1996. (75) Inventors: Dana M. Fowlkes, Chapel Hill, NC Lu, et al., Expression of Thioredoxin Random Peptide (US); Brian K. Kay, Madison, WI Libraries On the Escherichia coli Cell Surface as Functional (US); Jeffrey A. Frelinger, Chapel Hill, Fusions to Flagellin. A System Designed for Exploring NC (US); Robin Parish Protein-Protein Interactions, Biotechnology, vol. 13, pp. Hyde-Deruyscher, Chapel Hill, NC 366-372, Apr. 1995. (US) Valadon, et al., Peptide Libraries Define the Fine Specificity of Antipolysaccharide Antibodies to Cryptococcus neofor mans, J. Mol. Biol., vol. 261, pp. 11-22, 1996. (73) Assignee: Karo Bio AB, Huddinge (SE) Giebel, L. et al., “Screening of Cyclic Peptide Phage Librar ies Identifies Ligands that Bind Streptavidin with High (*) Notice: Subject to any disclaimer, the term of this Affinities”, Biochemistry 34:15430–15435 (1995). patent is extended or adjusted under 35 Kay, Brian K., et al., “An M13 phage library displaying U.S.C. 154(b) by 0 days. random 38-amino-acid peptides as a Source of novel sequences with affinity to seleted targets', Gene 128:59-65 (21) Appl. No.: 09/069,827 (1993). Lam, Kit S. et al., “A new type of Synthetic peptide library for identifying ligand-binding activity' Nature 354:82-84 (22) Filed: Apr. 30, 1998 (1991).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Use of Topical Anesthetics for the Manufacture of A
    Europäisches Patentamt *EP000682514B1* (19) European Patent Office Office européen des brevets (11) EP 0 682 514 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 31/00, A61K 31/19, of the grant of the patent: A61K 31/135 12.09.2001 Bulletin 2001/37 (86) International application number: (21) Application number: 94907887.7 PCT/US94/00901 (22) Date of filing: 25.01.1994 (87) International publication number: WO 94/17790 (18.08.1994 Gazette 1994/19) (54) USE OF TOPICAL ANESTHETICS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BRONCHIAL ASTHMA VERWENDUNG VON LOKALANAESTHETIKA ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON BRONCHIALASTHMA UTILISATION D’ANESTHESIANTS A USAGE LOCAL POUR LA REALISATION D’UN MEDICAMENT DESTINE AU TRAITEMENT DE L’ASTHME BRONCHIQUE (84) Designated Contracting States: (74) Representative: Matthews, Derek Peter et al AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL Frank B. Dehn & Co., PT SE European Patent Attorneys, 179 Queen Victoria Street (30) Priority: 02.02.1993 US 12343 London EC4V 4EL (GB) (43) Date of publication of application: (56) References cited: 22.11.1995 Bulletin 1995/47 FR-M- 3 385 (73) Proprietor: MAYO FOUNDATION FOR MEDICAL • PNEUM.POL. vol. 50, no. 5-6 , 1982 pages 269 - EDUCATION AND RESEARCH 273 MARYLA KRASNOWSKA ET AL. ’A test of Rochester, MN 55905 (US) lidocaine usage in the treatment of bronchial asthma’ (72) Inventors: • KLIN.MED. vol. 45, no. 5 , 1967 page 50-54 • GLEICH, Gerald J. V.N.SAPEROV ’The treatment of bronchial Rochester, MN 55902 (US) asthma with the aid of intra-arterial injections of • OHNISHI, Tsukasa novocain’ Tokyo (JP) • RESPIRATION vol.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • Ep 0932416 B1
    Europäisches Patentamt *EP000932416B1* (19) European Patent Office Office européen des brevets (11) EP 0 932 416 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 45/06, A61K 31/485, of the grant of the patent: A61K 31/165, A61K 31/135, 22.06.2005 Bulletin 2005/25 A61K 31/00, A61K 31/275 (21) Application number: 97910772.9 (86) International application number: PCT/US1997/017828 (22) Date of filing: 06.10.1997 (87) International publication number: WO 1998/015275 (16.04.1998 Gazette 1998/15) (54) METHOD AND POTENTIATED COMPOSITION FOR TREATING MIGRAINE VERFAHREN UND POTENZIERTE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON MIGRÄNE THERAPIE ET COMPOSITION PHARMACEUTIQUE POTENTIALISEE EFFICACES CONTRE LA MIGRAINE (84) Designated Contracting States: • DHAVARE ET AL: "Effect of Drugs Influencing AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC Central 5-HT Mechanisms on NL PT SE Amantadine-Induced Stereotyped Behaviour in the Rat" INDIAN JOURNAL PHYSIOL. (30) Priority: 09.10.1996 US 727923 PHARMACOL., vol. 27, no. 1, 1983, pages 19-24, 24.10.1996 US 736370 XP002058885 • MAJ T ET AL: "Antagonistic Effect of (43) Date of publication of application: Cyproheptadine on Neuroleptic-Induced 04.08.1999 Bulletin 1999/31 Catalepsy" PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 3, no. 1, 1975, pages 25-27, (73) Proprietor: Algos Pharmaceutical Corporation XP002058886 Neptune, NJ 07753 (US) • SKUZA ET AL: "Memantine, Amantadine and L-Deprenyl Potentiate the Action of L-DOPA in (72) Inventor: CARUSO, Frank, S. Monoamine-Depleted Rats" JOURNAL OF Colts Neck, NJ 07722 (US) NEURAL TRANSMISSION, vol.
    [Show full text]
  • Bbm:978-1-4684-7173-1/1.Pdf
    Index ACRYLONITRILE A Acetophenetidin, see: Phenacetin Abietic acid, detn - 464, 1590 Acetopropionic acid, see: Levulinic acid Abietic-type acids, detn - 70 Acetovanillone, detn - 150, 1211 Abietinic acid, see: Abietic acid Acetoxime, ref to spectrum - 1427 Acaricides, see individual com- p-Acetylaminobenzaldehyde thio- pounds semicarbazone, detn Accelerators (rubber) 696, 830, - 883, 1055 834, 849 Acetylcarbromal, detn - 1403 See also individual compounds Acetylcodeine - 1067 Acenaphthylene, detn - 63 Acetylene, detn in air - 1193 Acetal formation, spectral changes Acetylenes, CC'C , detn of traces due to - 320 5 - 1279 Acetaldehyde, detn Acetylenic compounds, detn as at 277 nm - 100 at 278 nm - 1185 mercuric acetate ad­ ducts - 1322 in acetic acid - 240 Acetylformic acid, see: Pyruvic as iodoform - 338 acid as thiosemicarbazone - 1271 Acetylisoniazid, detn - 110 in vinyl acetate - 241, 755, 3-Acetyl-6-methyl-2 ,4-pyrandione, 1090 p-Acetamidophenol, detn - 821, 822 see: Dehydroacetic 5-Acetamido-1,3,4-thiadiazole-2- acid thiol, detn - 824 N-Acetylmuramide glycahohydro­ Acetanilide, detn - 415, 1232 lase, see: Lysozyme Acetate, detn - 817 Acetylsalicyclic acid, Acetazolamide, detn - 760, 824 detn in drug mixt - 650, 750, Acetic acid, 880, 927, 1402, 1403, acetaldehyde in - 240 1404 hydrolysis of - 401 water in - 210 in phenobarbital - 280 Acetoacetate, detn - 1581 Acetoacetyl coenzyme A, detn - 461 mixt with salicylic acid - 261, Acetoacetyl thiol esters, absorption 1461 " a -Acids," detn in beer and wort of - 461 - 1226 Acetone, detn at 265 nm - 1185 Acids, organic, detn - 386 at 280 nm - 87 See also individual compounds in diacetone alcohol - 91 Aconite alkaloids, detn - 1019 as iodoform - 338, 1434 Acraldehyde, detn - 1185 in vinyl acetate 242, 1090 Acrilan, ref to reflectance spec- Acetone oxime, ref to spectrum - trum - 1455 1427 Acrolein, detn - 1185 3-(a-Acetonylbenzyl)-4-hydroxy- Acrylaldehyde, detn - 1185 coumarin, detn Acrylic acid - 852, 1334 at 308 nm - 304 Acrylonitrile ;.
    [Show full text]
  • US5276032.Pdf
    ||||||||||I|| USOO5276.032A United States Patent (19) 11 Patent Number: 5,276,032 King et al. 45) Date of Patent: Jan. 4, 1994 54 VISION AD AND ANESTHETC 56) References Cited COMPOSTON U.S. PATENT DOCUMENTS 1,907,392 5/1933 Stover ... ... 514/535 76) Inventors: O. Newton King, 2524 Yale Rd.; 2,382,546 8/1945 Curtis .... ... 54/535 X Henry W. Buck, 306 Homestead Dr., 2,803,582 8/1957 Cherney...... ... S4/535 X both of, Lawrence, Kans, 66049 3,019,163 1/1962 Harnist et al. ... 54/535 X 4,748,022 5/1988 Busciglio .......................... 424/95. FOREIGN PATENT DOCUMENTS 21 Appl. No.: 788,932 460629 1/1937 United Kingdom . Primary Examiner-Frederick E. Waddell 22) Fied: Nov. 7, 1991 Assistant Examiner-T. J. Criares 57 ABSTRACT Related U.S. Application Data A new visualizing and anesthetic composition and the process for the preparation thereof. The composition, 63 Continuation of Ser. No. 458,300, Dec. 28, 1989, aban generally as a gel, contains an effective amount of a doned. topical anesthetic, an effective amount of a visualizing agent and a pharmaceutically acceptable gelling reser 51 Int. Cl. ................. A61K 31/535; A61K 31/445; voir as a heat exchanger and/or a light transmitter. The A61K 31/24; A61K 47/00 composition is useful for topical application to a region (52) U.S. C. ................................. 514/239.2; 514/317; of mammalian skin to supply visualization to a lesion 514/535; 514/626, 514/536; 514/781; 514/944; therein and to anesthetize the region for a subsequent 514/967; 514/969 destructive therapy.
    [Show full text]
  • Ep 1646400 B1
    (19) & (11) EP 1 646 400 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/00 (2006.01) C07K 14/47 (2006.01) 21.07.2010 Bulletin 2010/29 A61P 37/06 (2006.01) A61P 37/08 (2006.01) (21) Application number: 04722319.3 (86) International application number: PCT/GB2004/001252 (22) Date of filing: 22.03.2004 (87) International publication number: WO 2004/082710 (30.09.2004 Gazette 2004/40) (54) TREATMENT OF ALLERGIC DISEASES USING A MODULATOR OF THE NOTCH SIGNALING PATHWAY BEHANDLUNG VON ALLERGISCHEN ERKRANKUNGEN UNTER VERWENDUNG EINES MODULATORS DES NOTCH SIGNALING PATHWAY TRAITEMENT DE MALADIES ALLERGIQUES UTILISANT UN MODULATEUR DE LA VOIE DE SIGNALISATION NOTCH (84) Designated Contracting States: (73) Proprietor: Celldex Therapeutics Limited AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Suite 54 HU IE IT LI LU MC NL PL PT RO SE SI SK TR Cambridge Designated Extension States: CB4 0EY (GB) LV (72) Inventors: (30) Priority: 21.03.2003 GB 0306583 • BODMER, Mark William, 21.03.2003 GB 0306582 Lorantis Limited 22.03.2003 GB 0306621 Cambridge CB4 0PE (GB) 22.03.2003 GB 0306622 • BRIEND, Emmanuel Cyrille Pascal, 22.03.2003 GB 0306626 Lorantis Limited 22.03.2003 GB 0306624 Cambridge CB4 OPE (GB) 22.03.2003 GB 0306640 • CHAMPION, Brian Robert, 22.03.2003 GB 0306644 Lorantis Limited 22.03.2003 GB 0306650 Cambridge CB4 0PE (GB) 22.03.2003 GB 0306651 • LENNARD, Andrew Christopher, 22.03.2003 GB 0306654 Lorantis Limited 04.04.2003 PCT/GB03/01525 Cambridge CB4 0PE (GB) 24.05.2003
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,747,060 Sackler Et Al
    US005747060A United States Patent (19) 11 Patent Number: 5,747,060 Sackler et al. 45) Date of Patent: May 5, 1998 54 PROLONGED LOCAL ANESTHESIA WITH IADR Abstracts 1982. Dental Research, 1990, Local Anes COLCHCNE thesia and Pain III, 3 pages. 75) Inventors: Richard Sackler, Greenwich; Paul Wall. et al., (Eds) Textbook of Pain, Third Edition, Publ. Goldenheim, Wilton, both of Conn.; Churchill Livingston, pp. 94-98. Mark Chasin, Manalapan, N.J. Devor. et al., 1991, A Group Report Mechanisms of Neu ropathic Pain Following Peripheral Injury, pp. 417-440. 73 Assignee: Euro-Celtique, S.A., Luxembourg. Luxembourg Devor, et al., 1983. Axoplasmic Transport Block Reduces Ectopic Impulse Generation in Injured Peripheral Nerves, 21 Appl. No.: 622,058 pp. 73-85. Schnebel. et al., The Use of Oral Colchicine for Low-Back 22 Filed: Mar. 26, 1996 Pain, 1987, pp. 354-357. (51) Int. Cl. ........................ A61K 9/14: A61K9/52 March, et al. Biodegradable Microspheres Containing a 52 U.S. Cl. ....................... 424/426; 424/195.1; 424/489: Colchicine Analogue Inhibit DNA Synthesis in Wascular 514/818: 514/825: 514/951; 514/963 Smooth Muscle Cells, 1994, pp. 1929-1933. 58) Field of Search ..................................... 514/818, 825. Dunn, et al. Monolithic Fibers For Controlled Delivery of 514/951, 963; 424/195.1, 489, 426 Tetracycline, 1980, pp. 157-159. (56) References Cited Lewis, et al. The Use Of In Vitro Release Methods to Guide the Development of Controlled-Release Formulations, U.S. PATENT DOCUMENTS Sourthern Research Institute. Alabama, pp. 61-64. 3,887,699 6/1975 Yoles ....................................... 424/19 Masters, et al., Prolonged Regional Nerve Blockade by 4001,388 1/1977 Shell ..
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]